The AVISE test is a blood test designed primarily to help diagnose systemic lupus erythematosus (SLE), commonly known as lupus. It screens for a panel of autoimmune biomarkers and uses a unique technology that detects complement activation on the surface of blood cells, giving it an edge over traditional antibody tests alone. The test is also used to differentiate lupus from other connective tissue diseases like rheumatoid arthritis, Sjögren’s syndrome, scleroderma, and polymyositis.
What the AVISE Test Measures
The AVISE Connective Tissue Disease (CTD) test combines two layers of information. The first is a standard panel of autoimmune antibodies, including markers commonly checked in rheumatology workups. The second, and more distinctive, layer involves something called cell-bound complement activation products, or CB-CAPs. These are fragments of the immune system’s complement proteins that attach to the surface of blood cells when the immune system is actively attacking the body’s own tissues.
Specifically, the test measures C4d molecules bound to red blood cells and B lymphocytes (a type of white blood cell). In people with lupus or early-stage lupus, C4d levels on circulating blood cells are significantly elevated compared to people with other inflammatory conditions or healthy individuals. Research has shown that C4d levels are elevated on all seven major types of circulating blood cells in lupus patients, including red blood cells, platelets, T cells, B cells, monocytes, and others.
Beyond the lupus-specific markers, the panel includes antibodies that help rule in or rule out other autoimmune conditions. These include anti-MCV (associated with rheumatoid arthritis), anti-SS-B/La (linked to Sjögren’s syndrome), anti-CENP (associated with a form of scleroderma), anti-Jo-1 (linked to polymyositis), and anti-Scl-70 (another scleroderma marker). When all of these disease-specific antibodies come back negative but the lupus markers are positive, it strengthens the case for a lupus diagnosis.
Why CB-CAPs Matter for Early Detection
Traditional lupus blood tests look for antibodies like ANA and anti-dsDNA. These are useful but imperfect. ANA is positive in many conditions that aren’t lupus, and anti-dsDNA can be negative in early or mild cases. The CB-CAP technology fills a gap by detecting immune activity that begins before a person meets full diagnostic criteria for lupus.
Research on patients with “pre-lupus,” meaning they had some lupus features but hadn’t yet qualified for a formal diagnosis, found that C4d levels on their blood cells were already as elevated as those in patients with established lupus. The only exceptions were C4d levels on T cells and B cells, which were slightly higher in confirmed lupus. This suggests that complement activation on blood cells starts early in the disease process, potentially offering a window to identify and treat lupus before it causes significant organ damage.
How Accurately It Predicts Lupus
One of the most compelling findings about the AVISE test is its ability to predict who will eventually be diagnosed with lupus. In a study tracking patients over two years, 53% of those who initially tested positive on the AVISE went on to receive a lupus diagnosis, compared to only about 10% of those who tested negative. That’s a meaningful difference for patients stuck in diagnostic uncertainty, which is common with lupus since it often takes years and multiple doctor visits to confirm.
The test also correlates with disease severity. Elevated B cell-bound C4d levels are associated with meeting more classification criteria for lupus and with higher scores on damage indices that track long-term organ involvement.
How Results Are Reported
AVISE results use a tiered scoring system rather than a simple positive or negative. The test first evaluates a set of tier 1 criteria, and if those are inconclusive, it moves to a tier 2 index score. A positive or moderate positive result (tier 1 positive, or tier 2 index above 0.1) indicates a higher likelihood of lupus. Results that fall at or below 0.1 on the tier 2 index are classified as negative, moderate negative, equivocal, or indeterminate, all grouped as “non-positive.”
Your rheumatologist will interpret these results alongside your symptoms, physical exam, and other lab work. A positive AVISE result doesn’t guarantee a lupus diagnosis on its own, but it significantly raises the probability and often prompts closer monitoring or earlier treatment.
What the Blood Draw Involves
The test requires two tubes of blood: one 10 mL tube collected in a lavender-top EDTA tube and one 5 mL tube in a serum separator tube. The samples need to be shipped on the same day the blood is drawn, using priority overnight delivery, and can only be shipped Monday through Friday. This timing requirement exists because the cell-bound markers degrade if the sample sits too long, so your doctor’s office will typically schedule your draw earlier in the week to avoid weekend delays.
Who Should Consider This Test
The AVISE test is most useful for people in a diagnostic gray zone. If you have symptoms like joint pain, fatigue, rashes, or mouth sores and your ANA is positive but your other labs are inconclusive, this test can help clarify whether lupus is the likely cause. It’s also valuable for patients diagnosed with “undifferentiated connective tissue disease,” a catch-all label used when symptoms suggest autoimmunity but don’t fit neatly into one condition. For these patients, the AVISE can signal whether progression to lupus is likely, helping guide treatment decisions before the disease advances.